|
|
|
This is the preliminary program for the 2009 Joint Statistical
Meetings in Washington, DC.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2009 Program page |
= Applied Session,
= Theme Session,
= Presenter
233
|
Mon, 8/3/09, 2:00 PM - 3:50 PM | CC-Hall D |
| Contributed Oral Poster Presentations: New Statistical Developments Advancing Biopharmaceutical Research - Contributed - Poster Presentations | ||
|
Biopharmaceutical Section, ENAR |
||
| Chair(s): Yang Yang, FDA | ||
| Poster Topic: Social and behavioral science: | ||
| 35: |
Analyzing Quality-of-Life Data —  Robert Norton, California State University, East Bay; Yan Yan Zhou, California State University, East Bay
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 36: |
Post-Randomization Subgroup: A Tale of Analysis in Early Responders — Yue Shentu, Merck & Co., Inc.
|
|
| Poster Topic: Applications and case studies: | ||
| 37: |
Rank-Based Adjustment of Baseline Imbalance in Assessing BOTOX® Dose-Dependent Response of Reducing Urinary Urge Incontinence in a Phase II Trial — Jihao Zhou, Allergan Pharmaceuticals, Inc.; Thomas Lin, Allergan Pharmaceuticals, Inc.; Corneliar Haag-Molkenteller, Allergan Pharmaceuticals, Inc.; Catherine Thompson, Allergan Pharmaceuticals, Inc.; Grace Daniell, Allergan Pharmaceuticals, Inc.; Anand Patel, Allergan Pharmaceuticals, Inc.; Brenda Jenkins, Allergan Pharmaceuticals, Inc.
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 38: |
A Fixed Study Design with Conditional Serial Assessment of Co-Primary Endpoints: An Application to a Single-Arm Pilot Oncology Trial — Jonathan Mahnken, The University of Kansas Medical Center; Jo Wick, The University of Kansas Medical Center; Byron J. Gajewski, The University of Kansas; Matthew S. Mayo, The University of Kansas Medical Center
|
|
| Poster Topic: Incomplete data analysis, imputation methods: | ||
| 39: |
NOCF! The future in Missing Data — Herbert Thijs, Hasselt University
|
|
| Poster Topic: QC, operation research, risk assessment: | ||
| 40: |
Nonparametric Tolerance Interval Approach for Specifications — Meiyu Shen, FDA; Yi Tsong, FDA
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 41: |
The Impact of Bioavailability on the Continual Reassessment Method — Jessica E. Pruszynski, Baylor University; Anna McGlothlin, Eli Lilly and Company; John W. Seaman, II, Baylor University
|
|
| Poster Topic: Biometrics, bioinformatics, computational biology: | ||
| 42: |
Visual Diagnostics for Pharmacokinetic Models — Xiaoyong Sun, Iowa State University; Dianne Cook, Iowa State University
|
|
| Poster Topic: Applications and case studies: | ||
| 43: |
Guidelines for the Analysis of FDG-PET Imaging Biomarkers — Patricia English, Pfizer Inc.; David Raunig, Pfizer Inc.; Santos Carvajal-Gonzalez, Pfizer Inc.; Yanwei Zhang, Pfizer Inc.
|
|
| Poster Topic: Longitudinal data, repeated measurements, and meta-analysis: | ||
| 44: |
Recurrent Events Data Analysis in Medical Device Trials — Cathy Zeng, Medtronic, Inc.
|
|
| Poster Topic: Reliability and survival modeling, risk analysis: | ||
| 45: |
A Comparison of Statistical Approaches for Cluster Randomized Trials with Survival Outcomes — Margaret R. Stedman, Brigham and Women's Hospital; David Gagnon, Boston University School of Public Health; Robert Lew, Boston University; Elena Losina, Boston University; Daniel Solomon, Brigham and Women's Hospital; M. Alan Brookhart, Brigham and Women's Hospital/Harvard Medical School
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 46: |
Biased Results from Single-Arm Phase II Cancer Clinical Trials: Simulations Based on a Large Clinical Trial — Hui Tang, Mayo Clinic; Nathan R. Foster, Mayo Clinic; Richard M. Goldberg, The University of North Carolina at Chapel Hill; Daniel Sargent, Mayo Clinic
|
|
| 47: |
Evaluation of the Randomized Placebo-Phase Design for Clinical Trials — Stephanie L. Shook, University of Pittsburgh; Howard Rockette, University of Pittsburgh
|
|
| Poster Topic: Mathematical statistics, distribution theory, robust statistics: | ||
| 48: |
Zero-Modified Negative Binomial Distribution as a Robust Family for Modeling Count Data — Qian Dong, Merck & Co., Inc.; Hongwei Wang, Merck & Co., Inc.; Arlene Swern, Merck & Co., Inc.; Eric C. Kleerup, University of California, Los Angeles
|
|
| Poster Topic: Incomplete data analysis, imputation methods: | ||
| 49: |
Comparison of Proportions of Composite Outcomes with Missing Values in their Components — Xianbin Li, FDA; Brian S. Caffo, Johns Hopkins Bloomberg School of Public Health
|
|
| Poster Topic: Semiparametric and nonparametric methods: | ||
| 50: |
A Semiparametric Survival Model — Ying Zhang, Merck Research Laboratories
|
|
| Poster Topic: Bayesian statistics, hierarchical models: | ||
| 51: |
A Comparison Study of General Linear Mixed Model and Permutation Tests in Group-Randomized Trials Under Non-Normal Error Distributions — Dongyue Fu, Quintiles, Inc.; David M. Murray, The Ohio State University; Seok Wong, University of Memphis
|
|
| Poster Topic: Biometrics, bioinformatics, computational biology: | ||
| 52: |
Design of Experiments for Genetic Network Identification — Theodore Allen, The Ohio State University; Cenny Taslim, The Ohio State University; Mario Lauria, The Telethon Institute of Genetics and Medicine
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 53: |
Optimal Treatment Allocation for a 2-Period, M Treatment Clinical Trial with Fixed Subject Total — Theodore C. Lystig, Boehringer Ingelheim Pharmaceuticals, Inc.
|
|
| Poster Topic: Experimental design: | ||
| 54: |
Efficacy with a Diamond Response Design — Charlie H. Goldsmith, McMaster University
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 55: |
Analyzing Intent-to-Treat Duration of Response — Ritwik Sinha, Bristol-Myers Squibb Company; Tai-Tsang Chen, Bristol-Myers Squibb Company; Chao Zhu, Bristol-Myers Squibb Company
|
|
| 57: |
Estimation of Treatment Retention: The Peak-Trough Ratio — William J. Coar, Gilead Colorado, Inc.; Darrin Despain, Gilead Colorado, Inc.; Brian L. Wiens, Gilead Sciences, Inc.
|
|
| 58: |
What If the Data Were Not Missing? — K. F. Yee, Akros Pharma Inc.
|
|
| 59: |
Beta-Mapping and Beta-Regression for Changes of Ordinal-Rating Measures on Likert Scales: A Comparison Among Multiple Treatment Groups — Kelly H. Zou, Pfizer Inc.; Martin O. Carlsson, Pfizer Inc.
|
|
| Poster Topic: Biometrics, bioinformatics, computational biology: | ||
| 60: |
A Semiparametric Copula Method on Building Oncology Association Network with Multiple Pathways, Genotypes, and Phenotypes — Le Bao, University of Washington; Zhou Zhu, Pfizer Inc.; Jingjing Ye, Pfizer Inc.
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 61: |
Making Decisions in Bioequivalence Studies: A Statistical Contribution — Arminda L. Siqueira, Universidade Federal de Minas Gerais; Daniela M. Braga, Agência Nacional de Saúde Suplementar - Ministério da Saúde; Paula R. Chellini, Centro de Pesquisa em Biotecnologia
|
|
| 62: |
Gender Differences in QTcF Based on Moxifloxacin Data — Moh-Jee C. Ng, FDA; Joanne Zhang, FDA; Lihan K. Yan, The George Washington University; Qianyu Dang, FDA
|
|
| Poster Topic: Clinical Trial Designs: | ||
| 63: |
Sample Size Determination in Clinical Trials with Multiple Co-Primary Binary Endpoints — Takashi Sozu, Osaka University; Tomoyuki Sugimoto, Osaka University Graduate School of Medicine; Toshimitsu Hamasaki, Osaka University Graduate School of Medicine
|
|
| 64: |
On the Three-Arm Noninferiority Trials with Binary Endpoints — Gang Li, GlaxoSmithKline; Shan Gao, Techdata LLC
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 65: |
A Likelihood-Based Model Adequacy Test of the Four-Parameter Logistic Model for Data with No Replicate Response — Wijith P. Munasinghe, Kansas State University; Kurex Sidik, Pfizer Global Research & Development
|
|
| Poster Topic: QC, operation research, risk assessment: | ||
| 66: |
Risk Assessment of Drug Product Content Uniformity Release Failure: A Bayesian Approach — David J. LeBlond, Abbott Laboratories
|
|
| Poster Topic: Pharmacokinetics and pharmacodynamics: | ||
| 67: |
Two Methods of Estimating Kel and Half-Life, Pharmacokinetic Considerations, and Statistical Tools — Peng Chai, MDS Pharma Services
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 68: |
A Bayesian Approach for Tailored Therapy Strategy: Hidden Markov Mixture ITP Model for Predicting Patient Response to Therapy — Wei Chen, University of Michigan; Haoda Fu, Eli Lilly and Company
|
|
| 69: |
Analysis of Recurrent Events Could Be Superior to the Time-to-First Event in Assessment of Drug Therapy in Patients with Arrhythmias — Hussein Al-Khalidi, STATKING Consulting, Inc.
|
|
| Poster Topic: Biometrics, bioinformatics, computational biology: | ||
| 70: |
Sample Size and Power Investigation for Exact McNemar Test — John D.S. Hwang, B.R.S.I.; James Lee, Daiichi Sankyo Pharma Development
|
|
| Poster Topic: Computational statistics, numerical methods, simulation: | ||
| 71: |
Using STATLIA for Bioassay Evaluation in Regulatory Environment — Lev Sirota, FDA; Boris G. Zaslavsky, FDA
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 72: |
A Multi-Stage, Model-Free Test of Synergy in Drug Combinations — Colleen Kelly, Exponent, Inc.; Ping Feng, National Base for Drug Clinical Trials; Toana Kawashima, Fred Hutchinson Cancer Research Center; Anja Wilmes, Victoria University of Wellington; John Miller, Victoria University of Wellington
|
|
| Poster Topic: Biometrics, bioinformatics, computational biology: | ||
| 73: |
Using Hierarchical Group Filters in High-Throughput Analysis to Improve the True Positive Discovery Rate — Shesh N. Rai, University of Louisville; Christopher N. Barnes, University of Louisville
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 75: |
Which MRI Measure is Best for Alzheimer's Disease Prevention Trials: Statistical Considerations of Power and Sample Size — Steven D. Edland, University of California, San Diego
|
|
| 76: |
Analyses of 'Favorite Data Sets from Drug Research' by Undergraduate Students — Sarah Downing, John Carroll University; Thomas H. Short, John Carroll University
|
|
| Poster Topic: Bayesian statistics, hierarchical models: | ||
| 77: |
A Bayesian Approach to Dose-Response Assessment and Synergy — Violeta G. Hennessey, The University of Texas M.D. Anderson Cancer Center
|
|
| Poster Topic: Clinical trials, drug discovery: | ||
| 78: |
Experiences in Outsourcing — Jennifer E. Hamer-Maansson, AstraZeneca Pharmaceuticals
|
|
| 79: |
Evaluation of Early Endpoints for Go-No Go Decisions in Late-Stage Drug Development — Linda Sun, Merck & Co., Inc.; Cong Chen, Merck Research Laboratories
|
|
| Poster Topic: Biometrics, bioinformatics, computational biology: | ||
| 80: |
Impact of Covariates on Feature Selection in Microarray Analysis — Elizabeth McClellan, Southern Methodist University ; Monnie McGee, Southern Methodist University; Richard Scheuermann, Pathology U.T. Southwestern Medical Center
|
|
|
JSM 2009
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |